
May 8 (Reuters) - Viatris Inc VTRS.O:
VIATRIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL XULANE LO™ LOW DOSE PATCH FOR BIRTH CONTROL IN WOMEN OF CHILDBEARING POTENTIAL
VIATRIS INC - NDA SUBMISSION TO FDA EXPECTED IN SECOND HALF OF 2025
VIATRIS INC - FAVORABLE SAFETY PROFILE WITH MILD-TO-MODERATE ADVERSE EVENTS
VIATRIS INC - XULANE LO ACHIEVES PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS